| Subgroups . | Study N . | Sample N . | RR (95% CI) . | P-value for subgroup difference . |
|---|---|---|---|---|
| Overall | 7 | 37 228 | 0.80 (0.67–0.95) | NA |
| Treatment duration | ||||
| <12 months | 3 | 196 | 0.73 (0.35–1.51) | 0.81 |
| ≥12 months | 4 | 37 032 | 0.80 (0.67–0.96) | |
| Therapy type | ||||
| Monotherapy | 2 | 13 902 | 0.84 (0.67–1.06) | 0.41 |
| Dual therapy | 5 | 23 326 | 0.73 (0.55–0.96) | |
| Baseline CVD | ||||
| ACS | 4 | 19 551 | 0.72 (0.53–0.98) | 0.77 |
| MI | 1 | 3799 | 1.31 (0.29–5.87) | |
| PAD | 1 | 13 842 | 0.70 (0.32–1.52) | |
| Comatose with cardiac arrest | 1 | 36 | 0.84 (0.67–1.05) |
| Subgroups . | Study N . | Sample N . | RR (95% CI) . | P-value for subgroup difference . |
|---|---|---|---|---|
| Overall | 7 | 37 228 | 0.80 (0.67–0.95) | NA |
| Treatment duration | ||||
| <12 months | 3 | 196 | 0.73 (0.35–1.51) | 0.81 |
| ≥12 months | 4 | 37 032 | 0.80 (0.67–0.96) | |
| Therapy type | ||||
| Monotherapy | 2 | 13 902 | 0.84 (0.67–1.06) | 0.41 |
| Dual therapy | 5 | 23 326 | 0.73 (0.55–0.96) | |
| Baseline CVD | ||||
| ACS | 4 | 19 551 | 0.72 (0.53–0.98) | 0.77 |
| MI | 1 | 3799 | 1.31 (0.29–5.87) | |
| PAD | 1 | 13 842 | 0.70 (0.32–1.52) | |
| Comatose with cardiac arrest | 1 | 36 | 0.84 (0.67–1.05) |
ACS, acute coronary syndrome; CVD, cardiovascular disease; MI, myocardial infarction; NA: not applicable; PAD, peripheral artery disease.
| Subgroups . | Study N . | Sample N . | RR (95% CI) . | P-value for subgroup difference . |
|---|---|---|---|---|
| Overall | 7 | 37 228 | 0.80 (0.67–0.95) | NA |
| Treatment duration | ||||
| <12 months | 3 | 196 | 0.73 (0.35–1.51) | 0.81 |
| ≥12 months | 4 | 37 032 | 0.80 (0.67–0.96) | |
| Therapy type | ||||
| Monotherapy | 2 | 13 902 | 0.84 (0.67–1.06) | 0.41 |
| Dual therapy | 5 | 23 326 | 0.73 (0.55–0.96) | |
| Baseline CVD | ||||
| ACS | 4 | 19 551 | 0.72 (0.53–0.98) | 0.77 |
| MI | 1 | 3799 | 1.31 (0.29–5.87) | |
| PAD | 1 | 13 842 | 0.70 (0.32–1.52) | |
| Comatose with cardiac arrest | 1 | 36 | 0.84 (0.67–1.05) |
| Subgroups . | Study N . | Sample N . | RR (95% CI) . | P-value for subgroup difference . |
|---|---|---|---|---|
| Overall | 7 | 37 228 | 0.80 (0.67–0.95) | NA |
| Treatment duration | ||||
| <12 months | 3 | 196 | 0.73 (0.35–1.51) | 0.81 |
| ≥12 months | 4 | 37 032 | 0.80 (0.67–0.96) | |
| Therapy type | ||||
| Monotherapy | 2 | 13 902 | 0.84 (0.67–1.06) | 0.41 |
| Dual therapy | 5 | 23 326 | 0.73 (0.55–0.96) | |
| Baseline CVD | ||||
| ACS | 4 | 19 551 | 0.72 (0.53–0.98) | 0.77 |
| MI | 1 | 3799 | 1.31 (0.29–5.87) | |
| PAD | 1 | 13 842 | 0.70 (0.32–1.52) | |
| Comatose with cardiac arrest | 1 | 36 | 0.84 (0.67–1.05) |
ACS, acute coronary syndrome; CVD, cardiovascular disease; MI, myocardial infarction; NA: not applicable; PAD, peripheral artery disease.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
